Rodriguez-Sevilla JJ, Ganan-Gomez I, Ma F, et al. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes.

Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.

Patients who experience a relapse of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) following a transplant can receive “moderate” benefits from a combination of venetoclax and ...

Key myelodysplastic syndrome pipeline therapies in various stages of development include MBG453, Tamibarotene, CA-4948, RVU120, TQB2618, AMG 176, SAR443579, Etavopivat, AG-946, Venetoclax ...

One patient assigned to ibrutinib-venetoclax developed myelodysplastic syndrome / acute myeloid leukemia (AML), as did eight patients assigned to FCR.

--AbbVie announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet the ...

Phase 1b/2 Study of Lisaftoclax (APG-2575) Combined with Azacitidine (AZA) in Patients with Treatment-Naïve or Prior Venetoclax-Exposed Myeloid Malignancies Abstract #: 6505 Format: Oral Presentation ...

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona ...

Venetoclax (Venclexta) combined with a hypomethylating agent (HMA) -- the standard of care for older patients with acute myeloid leukemia (AML) -- appeared to be safe and effective in patients in ...

And I think we'll get into, you know, the probably greatest unmet need is, once we do fail HMA-based therapy, particularly for higher risk myelodysplastic syndrome patients, there's really nothing.